Table 3.
Associations of single htSNP in IL1B with lung cancer risk.
| Type/modela/rs | Genotype | Controls 633 n (%) |
Cases 627 n (%) |
OR (95 CI)b,c | P valuec | AICd |
|---|---|---|---|---|---|---|
| Whole group: lung cancer | ||||||
| rs1143633 (A>G) | ||||||
| Co-dominant | A/A | 169 (28.2%) | 224 (36.4%) | 1.00 | ||
| G/A | 311 (51.9%) | 289 (47%) | 0.68 (0.53–0.89) | 0.0044 | 1651.4 | |
| G/G | 119 (19.9%) | 102 (16.6%) | 0.62 (0.44–0.87) | |||
| Dominant | A/A | 169 (28.2%) | 224 (36.4%) | 1.00 | ||
| G/A-G/G | 430 (71.8%) | 391 (63.6%) | 0.67 (0.52–0.85) | 0.0012 | 1649.7 | |
| Recessive | A/A-G/A | 480 (80.1%) | 513 (83.4%) | 1.00 | ||
| G/G | 119 (19.9%) | 102 (16.6%) | 0.78 (0.58–1.05) | 0.1 | 1657.6 | |
| Over-dominant | A/A-G/G | 288 (48.1%) | 326 (53%) | 1.00 | ||
| G/A | 311 (51.9%) | 289 (47%) | 0.81 (0.65–1.02) | 0.077 | 1657.1 | |
| Log-additive | – | – | – | 0.77 (0.65–0.91) | 0.0021 | 1650.8 |
| rs3136558 (T>C) | ||||||
| Co-dominant | T/T | 223 (37.2%) | 214 (34.8%) | 1.00 | ||
| C/T | 296 (49.4%) | 293 (47.6%) | 1.02 (0.79–1.31) | 0.079 | 1657.2 | |
| C/C | 80 (13.4%) | 108 (17.6%) | 1.46 (1.03–2.06) | |||
| Dominant | T/T | 223 (37.2%) | 214 (34.8%) | 1.00 | ||
| C/T-C/C | 376 (62.8%) | 401 (65.2%) | 1.11 (0.88–1.41) | 0.38 | 1659.5 | |
| Recessive | T/T-C/T | 519 (86.6%) | 507 (82.4%) | 1.00 | ||
| C/C | 80 (13.4%) | 108 (17.6%) | 1.44 (1.05–1.98) | 0.025 | 1655.2 | |
| Over-dominant | T/T-C/C | 303 (50.6%) | 322 (52.4%) | 1.00 | ||
| C/T | 296 (49.4%) | 293 (47.6%) | 0.91 (0.73–1.15) | 0.44 | 1659.6 | |
| Log-additive | – | – | – | 1.16 (0.99–1.37) | 0.073 | 1657 |
| rs1143630 (C>A) | ||||||
| Co-dominant | C/C | 422 (70%) | 407 (66.9%) | 1.00 | ||
| A/C | 164 (27.2%) | 190 (31.2%) | 1.19 (0.92–1.53) | 0.21 | 1655.7 | |
| A/A | 17 (2.8%) | 11 (1.8%) | 0.67 (0.31–1.46) | |||
| Dominant | C/C | 422 (70%) | 407 (66.9%) | 1.00 | ||
| A/C-A/A | 181 (30%) | 201 (33.1%) | 1.14 (0.89–1.46) | 0.29 | 1655.7 | |
| Recessive | C/C-A/C | 586 (97.2%) | 597 (98.2%) | 1.00 | ||
| A/A | 17 (2.8%) | 11 (1.8%) | 0.64 (0.29–1.38) | 0.25 | 1655.5 | |
| Over-dominant | C/C-A/A | 439 (72.8%) | 418 (68.8%) | 1.00 | ||
| A/C | 164 (27.2%) | 190 (31.2%) | 1.21 (0.94–1.55) | 0.15 | 1654.7 | |
| Log-additive | – | – | – | 1.07 (0.86–1.33) | 0.54 | 1656.5 |
| Histopahtology subgroup: lung squamous cell carcinomae | ||||||
| rs1143633 (A>G) | ||||||
| Log-additive | – | – | – | 0.59 (0.47–0.75) | < 0.0001 | 980.8 |
| rs3136558 (T>C) | ||||||
| Log-additive | – | – | – | 1.35 (1.08–1.69) | 0.0086 | 994.5 |
aDominant model: AB (Heterozygote) + BB (Homozygous variant-type) versus AA (Homozygous wild-type), Recessive model: BB versus AA + AB, Co-dominant model: AB versus AA and BB versus AA, Over-dominant model: AB versus AA + BB, Log-additive model: Analysis of trend where AA is ‘0’, AB is ‘1’ and BB is ‘2’.
bOR (odd ratio), 95% CI (95% confidence interval), adjusted for smoking duration.
cBoldface indicates statistical significance.
dAkaike’s Information Criterion.
eOnly list the best significant models.